SELUTION SLR™ Drug-Eluting Balloon Approved by FDA for In-Stent Restenosis: First and Only Sirolimus Drug-Eluting Balloon in the US
Cordis, a global leader in interventional cardiovascular and endovascular technologies, today announced that the U.S. Food and Drug Administration (FDA) has approved the SELUTION SLR™ (Sustained Limus Release) Drug-Eluting Balloon (DEB) for the treatment of coronary in-stent restenosis (ISR), marking a major milestone in expanding treatment options for one of the most complex challenges in interventional cardiology. Physicians now have immediate access to the SELUTION SLR™ DEB, a next-generation drug-eluting balloon designed to deliver sustained sirolimus therapy without leaving a permanent implant behind.
Cordis Launches SELUTION SLR™ PTA Drug-Eluting Balloon (DEB) in Japan
Cordis, a global leader in interventional cardiovascular technologies, today announces the launch and availability of the SELUTION SLR™ PTA Drug-Eluting Balloon (DEB)1 for use in Japan.
Cordis to Present SELUTION SLR™ Drug-Eluting Balloon Clinical Data at CRT 2026
Cordis, a global leader in interventional cardiovascular technologies, will highlight insights from the SELUTION SLR™ Drug-Eluting Balloon (DEB) clinical trial program at Cardiovascular Research Technologies (CRT) 2026, March 7–10 in Washington, D.C. Presentations will include the 12-month results of SELUTION4ISR and SELUTION DeNovo trials along with new subset analyses from the SELUTION DeNovo study.
